Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
GH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.14 - $63.48
Previous CloseN/A
Volume639.07K
Average Volume (3M)2.85M
Market Cap
$7.91B
Enterprise Value$7.16B
Total Cash (Recent Filing)$629.14M
Total Debt (Recent Filing)$1.33B
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Oct 30, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding124,705,860
10 Day Avg. Volume2,485,288
30 Day Avg. Volume2,847,351
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue8.64
Enterprise Value/Gross Profit13.75
Enterprise Value/Ebitda-19.45
Forecast
1Y Price Target
$61.86Price Target Upside-2.48% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGH delivered a strong beat across all its clinical products with particular strength in Screening (Shield) and raised its full-year guide again, expecting more than double in screening revenue.
Market LeadershipGuardant remains the best-in-class liquid biopsy opportunity with its market-leading G360 assay in late-stage cancer testing and its growing portfolio with Reveal MRD and Shield CRC screening.
Regulatory And ReimbursementThere is early interest from the administration in providing Medicare reimbursement to breakthrough devices, which could positively impact Shield MCED.
Bears Say
Competitive PressureUpcoming blood-based colorectal cancer screening data from a competitor may cause a near-term overhang for Guardant Health shares.
Investor ConcernsCommentary on Shield V2 overshadowed some of the overperformance, as management appeared cagey about updates on expectations for V2 data release and approval.
Product DelaysThe perceived delay and no formal timeline for V2 data unveiling is likely to impact investor positioning, especially in the near term.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $20.14 and its highest was $63.48 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $7.91B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Oct 30, 2025 which is in 63 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Jul 30, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.741 by -$0.059.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Overvalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.79.
How many shares outstanding does Guardant Health have?
Guardant Health has 124,705,860 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.741. Following the earnings report the stock price went down -9.316%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.86 (-2.48% Downside)
$61.86 (-2.48% Downside)
Blogger Sentiment
Bullish
GH Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.21%
12-Months-Change
Fundamentals
Return on Equity
-4584.47%
Trailing 12-Months
Asset Growth
-17.23%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health (GH) is a precision oncology company focused on transforming cancer care through innovative blood testing technology. Operating primarily in the healthcare sector, Guardant Health specializes in non-invasive genomic sequencing and analysis of circulating tumor DNA (ctDNA) to aid in cancer diagnosis, treatment selection, and monitoring. Its core products include the Guardant360 and GuardantOMNI tests, which offer comprehensive genomic insights to oncologists and help guide personalized treatment plans for cancer patients.
GH Company Deck
GH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter for Guardant Health with significant revenue growth, successful product launches, and improved gross margins. Despite some uncertainties regarding the timing of Shield V2 data and Medicare reimbursement processes, the company's strong performance and raised revenue guidance indicate a positive outlook.View all GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$61.86
▼(-2.48% Downside)
Technical Analysis
Ownership Overview
3.84% Insiders
28.35% Mutual Funds
39.31% Other Institutional Investors
12.37% Public Companies and Individual Investors